What are the American Academy of Dermatology recommendations for monitoring patients receiving immune checkpoint inhibitors for primary cutaneous melanoma?

Updated: Oct 13, 2020
  • Author: Susan M Swetter, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Answer

Patients being treated with immune checkpoint inhibitors should undergo dermatologic evaluation within the first month of therapy, with such assessment being continued as needed to manage dermatologic adverse effects.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!